Autopsy report · NCT03192215
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Cause of deathFutility
“The DSMB halted the trial prematurely due to futility without any safety concerns.”
Life of this trial
- Registered 7 months before it started.
- Ran for about 5 years 3 months before it stopped.
- 1,015 participants enrolled.
- Results were posted on the registry 2 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Columbia University
- Sponsor type
- University, hospital or other
- Conditions
- Stroke
- Interventions
- Apixaban; Aspirin
- Participants
- 1,015
- Sites
- 177
- Countries
- Canada, United States
Trials that died the same way
- Helping HIV Infected Patients in South Africa Adhere to Drug Regimens
“DSMB stopped trial for futility” - Interventional Management of Stroke (IMS) III Trial
“NINDS/NIH-DSMB recommended halting trial due to futility, no safety concerns.” - Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery
“DSMB stopped the study based on conclusion of likely futility of treatment on the primary outcome.” - ATG Plus Low-dose PT-Cy for GVHD Prevention
“DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.” - Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
“NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.